Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus IMPAVIDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus IMPAVIDO.
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE vs IMPAVIDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a mitochondrial electron transport inhibitor that selectively targets the cytochrome bc1 complex, disrupting pyrimidine synthesis in Plasmodium. Proguanil hydrochloride is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. The combination synergistically inhibits plasmodial replication.
Miltefosine, the active ingredient in IMPAVIDO, is an alkylphosphocholine with antileishmanial activity. It interacts with cell membrane phospholipids, inhibits cytochrome c oxidase, and induces apoptosis-like cell death in Leishmania parasites. It also modulates host immune responses.
250 mg atovaquone/100 mg proguanil hydrochloride (1 tablet) orally once daily for prophylaxis; 4 tablets (1000 mg/400 mg) orally once daily for 3 consecutive days for treatment.
60 mg/kg body weight per day (2.5 mg/kg per hour) by intravenous infusion over 6 hours, up to a maximum of 150 mg/day, for 21 days.
None Documented
None Documented
Atovaquone: terminal half-life 2-3 days (67-83 hours); prolonged to 4-5 days in malaria due to drug accumulation. Proguanil: terminal half-life 12-21 hours; cycloguanil 14-21 hours.
Terminal elimination half-life is approximately 16-21 days in adults; may be longer in severe hepatic impairment.
Atovaquone: >94% excreted unchanged in feces via biliary elimination; renal excretion minimal (<1%). Proguanil: ~40-60% excreted renally as unchanged drug and metabolites (primarily cycloguanil and 4-chlorophenylbiguanide).
Primarily renal (over 90% as unchanged drug); fecal excretion is minimal (<5%).
Category A/B
Category C
Antiprotozoal
Antiprotozoal